WE PERCEIVE. WE PREPARE. WE PROTECT.

Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

We’re pleased to announce that Joseph C. Papa is Emergent’s new president and chief executive officer, beginning a new era of empowering communities, protecting public health, and returning to growth.

LEARN MORE

Continuing 25 years of protecting against public health threats

Whether it’s increasing access to NARCAN® Nasal Spray, which is helping combat the opioid epidemic, or continuing to deliver vaccines and therapeutics, Emergent’s focus remains on protecting communities and addressing the evolving landscape of global health challenges.

LEARN MORE

Joseph C. Papa

Capabilities

We are a leader in providing solutions that address public health threats and bring lifesaving, life-extending products to market.

  • Commercial Products

    We offer commercialized products that address endemic public health threats such as the opioid epidemic.

  • Medical Countermeasures

    Emergent specializes in developing, manufacturing, and stockpiling medical countermeasures for military and civilian populations that target some of the deadliest public health threats.

  • Bioservices

    Emergent offers molecule-to-market drug substance and drug product development and manufacturing services to biopharma innovators, government, and non-government organizations.

Woman in Lab

At Emergent, our mission is to protect and enhance life.

View our 2023 Annual Report

Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis

GAITHERSBURG, Md., March 28, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) remains committed to fighting the ongoing opioid crisis by broadening access to, and awareness of, NARCAN® Nasal Spray to help save lives in opioid overdose emergencies. One year after Emergent obtained the historic OTC U.S. FDA approval in March 2023 and seven months since retail launch in August 2023, the availability of NARCAN® Nasal Spray in pharmacies, grocery stores and online retailers has helped more people gain access to this life-saving product. Emergent and other stakeholders in the fight must continue raising awareness about the availability of products like NARCAN® Nasal Spray, reducing stigma and further improving access for all Americans.
Read More

Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility

GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed “No Action Indicated” or NAI status classification for the company's Baltimore Bayview manufacturing facility. Based on this outcome, the Baltimore Bayview facility is considered to be in an acceptable state of compliance with regard to current good manufacturing practices (cGMP).
Read More

Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results

GAITHERSBURG, Md., March 06, 2024 -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2023.
Read More
READ ALL NEWS

This website uses cookies. This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Notice and Terms of Use.